ArticleHeliyon2024

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines - A prospective multi-center study.

Pawat Phuensan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.